Building on the experience gained from developing ultra-long acting veterinary insulins, Akston has developed a novel human insulin candidate – AKS-440. This is intended to be a once-a-week injectable diabetes therapy that uses a modified human Fc region paired with a designer insulin. It is currently in pre-clinical development.

Back to Pipeline